Q1 EPS Estimate for Oric Pharmaceuticals Lifted by Analyst

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) – Equities researchers at HC Wainwright upped their Q1 2026 EPS estimates for Oric Pharmaceuticals in a research note issued on Tuesday, February 24th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.31) per share for the quarter, up from their previous estimate of ($0.37). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Oric Pharmaceuticals’ current full-year earnings is ($2.17) per share. HC Wainwright also issued estimates for Oric Pharmaceuticals’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.34) EPS and FY2026 earnings at ($1.28) EPS.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04.

ORIC has been the topic of a number of other reports. Wall Street Zen downgraded Oric Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 23rd. Piper Sandler started coverage on Oric Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “overweight” rating and a $22.00 target price for the company. Wolfe Research began coverage on shares of Oric Pharmaceuticals in a report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Wells Fargo & Company lifted their price target on shares of Oric Pharmaceuticals from $19.00 to $25.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Thursday, January 22nd. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Oric Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $20.20.

Oric Pharmaceuticals Trading Up 0.7%

Shares of ORIC opened at $13.50 on Thursday. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -8.88 and a beta of 1.35. The business’s fifty day simple moving average is $10.28 and its two-hundred day simple moving average is $10.97. Oric Pharmaceuticals has a 12 month low of $3.90 and a 12 month high of $14.93.

Insider Activity

In other news, CFO Dominic Piscitelli sold 52,000 shares of the company’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total transaction of $702,520.00. Following the completion of the sale, the chief financial officer owned 68,148 shares of the company’s stock, valued at $920,679.48. This represents a 43.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jacob Chacko sold 33,374 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total transaction of $302,368.44. Following the completion of the transaction, the chief executive officer directly owned 581,711 shares in the company, valued at approximately $5,270,301.66. The trade was a 5.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 106,814 shares of company stock valued at $1,199,135 in the last quarter. 6.82% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oric Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Orbimed Advisors LLC increased its stake in shares of Oric Pharmaceuticals by 305.0% in the 3rd quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock worth $43,701,000 after purchasing an additional 2,742,475 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new stake in Oric Pharmaceuticals during the fourth quarter valued at about $19,642,000. State Street Corp increased its position in Oric Pharmaceuticals by 77.1% in the fourth quarter. State Street Corp now owns 4,258,397 shares of the company’s stock worth $34,834,000 after buying an additional 1,854,458 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Oric Pharmaceuticals by 48.8% in the third quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock worth $55,802,000 after buying an additional 1,525,445 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Oric Pharmaceuticals by 3,646.1% in the second quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock worth $13,555,000 after buying an additional 1,299,799 shares during the period. Institutional investors own 95.05% of the company’s stock.

Key Stories Impacting Oric Pharmaceuticals

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a Buy and raised modeling for 2026 EPS while maintaining a $25 price target, signaling stronger analyst conviction and upside versus current levels. Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright
• Positive Sentiment: Street consensus of analyst price targets (per Zacks) implies roughly a 58.4% upside, which can attract momentum buyers and analysts if sentiment persists. Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here’s is How to Trade
• Positive Sentiment: Oric reported an EPS beat for the most recent quarter (reported -$0.30 vs. consensus -$0.34), which likely underpins recent buying interest and supports upward revisions. Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 7.9% Following Earnings Beat
• Positive Sentiment: Wedbush assigned an Outperform rating, adding another credible source of bullish coverage that can influence institutional demand. Oric Pharmaceuticals (NASDAQ:ORIC) Earns “Outperform” Rating from Wedbush
• Neutral Sentiment: Analyses assessing ORIC’s valuation after Phase 1b data and a US$264M capital raise note improved cash runway but also highlight dilution and execution risk — a mixed signal that may temper enthusiasm unless clinical progress continues. Assessing ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Data And US$264 Million Capital Raise
• Negative Sentiment: An insider — CFO Dominic Piscitelli — sold 52,000 shares at about $13.51, reducing his holdings by ~43%, which some investors view as a negative signal about near-term insider conviction. The sale was disclosed via SEC filing. Insider sale: Dominic Piscitelli Form 4

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.